OR WAIT null SECS
Recro Pharma changed its name to Societal CDMO to reflect the company’s expansion as a result of the acquisition of IriSys.
Recro Pharma announced on March 21, 2022 that it changed its name to Societal CDMO. The name change reflects the expansion and transformation of the company as a result of the acquisition and integration of IriSys, a contract development and manufacturing organization (CDMO) focused on product development and good manufacturing practice (GMP) manufacturing.
Societal CDMO focuses on solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development. The addition of IriSys in August 2021 expanded the company’s physical footprint to include facilities on both US coasts, diversification of its customer base, more service offerings, and enhancement of its industry expertise. The services of the company will now encompass therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, and packaging and logistic services to the global pharmaceutical market.
“When we set out to rebrand Recro, we sought a name and identity that carried with it a purpose, one which exemplified the commitment our employees demonstrate every day to making a positive impact within communities across the country and around the world,” said David Enloe, CEO of Societal CDMO, in the press release. “At the same time, we were also focused on effectively communicating our evolution as a partner to our clients, as well as our people, both today and in the future. We believe the name Societal CDMO, along with our new tagline of ‘Bringing Science to Society,’ captures not only where we find ourselves as a company today, but it reflects our inspiration for future growth as an organization.”